Moreover, as NKG2DL are frequently downregulated or absent on leukemia blasts and leukemic stem cells [3,58,59], the upregulation of B7-H6 by GSK-3α inhibition could provide an additional therapeutic target to enhance NK cell reactivity against leukemia cells. Here, NCR3LG1 is linked to leukemia.